What Compass Therapeutics does

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing next-generation antibody therapeutics that target the immune synapse to overcome resistance to anti-angiogenic and checkpoint inhibitor therapies. The company operates a platform-plus-pipeline model: a proprietary antibody discovery engine combining a common light chain-focused antibody discovery platform, a mammalian human display platform for antibody tuning, and the StitchMabs™ high-throughput multispecific screening platform that covalently links monoclonal antibodies into customized bispecific formats. This platform has drugged more than 40 immune targets and generated thousands of epitopically and functionally varied candidates. The pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody in Phase 2/3 (COMPANION-002) for second-line biliary tract cancer, which met its primary ORR endpoint (17.1% vs 5.3%, p=0.031) and PFS secondary endpoint (HR=0.44, p<0.0001) but missed overall survival due to 54% patient crossover. Additional clinical assets include CTX-471 (CD137 agonist), CTX-8371 (PD-1 x PD-L1 bispecific, 33% ORR in checkpoint-fail patients), and CTX-10726 (PD-1 x VEGF-A, IND cleared Q1 2026).

The company's revenue model is entirely pre-commercial. Compass has no approved products, generates no product revenue, and is funded through equity financings — most recently a $129 million public offering in 2025 — with $195 million in cash and marketable securities as of Q1 2026 providing runway into 2028. Net losses were $66.5 million in 2025 and $18.3 million in Q1 2026. Future revenue is expected to come from direct commercialization of proprietary oncology therapeutics (initially tovecimig) supported by the appointment of a Chief Commercial Officer in January 2026, supplemented by potential platform licensing and discovery collaborations. Compass is publicly listed on NASDAQ under ticker CMPX, headquartered in Boston, and was co-founded in 2014 by Thomas J. Schuetz, MD, PhD following his tenure as a venture partner at OrbiMed.

The company's customer-facing motion is currently clinical-trial-driven: investigational therapies are delivered exclusively through 25+ U.S. academic medical centers and community oncology sites (Mayo Clinic, MD Anderson, Mass General, UCSF, Stanford, Johns Hopkins) participating in multi-center studies. Following the planned BLA submission for tovecimig later in 2026, the company intends to transition to an enterprise field sales model for commercial launch in biliary tract cancer and other oncology indications.

Name

Compass Therapeutics

Legal name

Compass Therapeutics, Inc.

Website

https://compasstherapeutics.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing next-generation bispecific antibody therapeutics to overcome resistance to anti-angiogenic and checkpoint inhibitor therapies. Its pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific in Phase 2/3 for biliary tract cancer, supported by a proprietary StitchMabs™ antibody discovery platform.

Ownership category

akta.pro rank

Product category

Clinical-stage Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Oncology antibody therapeutics
• Bispecific antibody development
• Immuno-oncology drug discovery
• Clinical-stage biopharmaceuticals
• Antibody discovery platforms

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue clinical-stage operations: Clinical-stage oncology biopharmaceutical company with no commercial product sales. Operations are funded through equity financings (e.g., $80M PIPE in 2022, $129M public offering, $400M mixed shelf offering filed December 2025). Net loss of $66.5 million in 2025 and $18.3 million in Q1 2026; cash and marketable securities of $195 million expected to fund operations into 2028 ahead of a planned BLA submission for tovecimig.
2. Future commercial drug sales (planned): Future revenue model centers on direct commercialization of proprietary oncology antibody therapeutics, beginning with tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody targeting biliary tract cancer, supported by the appointment of a Chief Commercial Officer in January 2026. Company is also actively seeking strategic partners and discovery collaborations around StitchMabs™ and common light chain platforms.

Pricing tiers

Go-to-market motion3 records

Distribution channels1 record

Marketing channels7 records

Core offering

Compass Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of proprietary antibody therapeutic candidates for oncology, anchored by the bispecific antibody tovecimig (CTX-009) targeting DLL4 and VEGF-A in biliary tract cancer, with additional bispecific (CTX-8371, CTX-10726) and agonistic monoclonal (CTX-471) candidates. The pipeline is generated and supported by two proprietary discovery platforms — the StitchMabs™ high-throughput multispecific antibody screening platform and a common light chain antibody discovery platform — which together have drugged more than 40 immune targets and produced thousands of monoclonal and multispecific candidates.

Product overview

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing a platform-plus-pipeline architecture. The foundation is a proprietary antibody discovery engine comprising the Common Light Chain Antibody Discovery Platform and the StitchMabs™ multispecific screening platform, which together allow the company to empirically generate and screen thousands of monoclonal and multispecific antibody candidates against more than 40 immune targets. On top of this platform sits a focused pipeline of antibody-based therapeutic candidates spanning multiple modalities and stages: the lead clinical asset Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody in Phase 2/3 for biliary tract cancer with a planned BLA submission; the clinical assets CTX-471 (CD137 agonist) and CTX-8371 (PD-1 x PD-L1 bispecific); the newly IND-cleared CTX-10726 (PD-1 x VEGF-A bispecific) entering Phase 1; and an ongoing discovery effort evaluating additional bispecifics and trispecifics that combine angiogenesis and immune-modulating targets.

Differentiator

Problem solved

Functional benefit

Products and services

• Tovecimig (CTX-009) Bispecific antibody simultaneously targeting DLL4 and VEGF-A, in development for second-line biliary tract cancer (with paclitaxel), third- and fourth-line metastatic colorectal cancer (monotherapy), and other DLL4-positive solid tumors. Phase 2/3 COMPANION-002 met primary ORR (17.1% vs 5.3%, p=0.031) and PFS (4.7 vs 2.6 months, HR=0.44, p<0.0001) endpoints; received FDA Orphan Drug Designation in April 2026.
• CTX-471 Agonistic monoclonal antibody directed against the co-stimulatory molecule CD137 (4-1BB) that delivers a potent costimulatory signal to activated T cells and other effector cells. Designed for patients with solid tumors and hematologic malignancies refractory to checkpoint inhibitor therapy; new NCAM-positive tumor basket study planned to initiate in Q1 2026.
• CTX-8371 Bispecific antibody simultaneously targeting PD-1 and PD-L1. Phase 1 expansion cohorts are being enrolled in NSCLC, TNBC, and Hodgkin lymphoma based on dose-escalation responses, with 33% ORR at top dose levels in patients who previously failed checkpoint inhibitor therapy.
• CTX-10726 Tetravalent bispecific antibody simultaneously targeting PD-1 and VEGF-A. Designed so that modulation of the tumor microenvironment via VEGF targeting improves the efficacy of PD-1 blockade. FDA-cleared IND with Phase 1 enrollment initiated in Q1 2026.
• StitchMabs™ Multispecific Antibody Screening Platform Proprietary, high-throughput multispecific antibody screening platform that covalently links two or more monoclonal antibodies, antibody fragments, or other biologics into customized bi- and multispecific formats in minutes using peptide tags for irreversible peptide bond formation, enabling large matrix screening experiments to identify novel and potentially unexpected synergistic combinations.
• Common Light Chain Antibody Discovery Platform Proprietary in vitro and in vivo platforms for the generation of highly diverse antibody panels based on a single light chain sequence. To date, more than 40 immune targets have been drugged, delivering thousands of epitopically and functionally varied leads that can be screened for combination synergy as cocktails or bispecifics, with bispecific candidates exhibiting monoclonal-like expression, stability, and pharmacokinetics.

Quantifiable outcome

• Progression-free survival of 4.7 months vs 2.6 months (HR=0.44, p<0.0001), representing a 56% reduction in risk of progression for tovecimig+paclitaxel vs paclitaxel alone in second-line biliary tract cancer (COMPANION-002 Phase 2/3)
• +5 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered flagship and minor.

• TRIGR TherapeuticsflagshipStrategic or Co-development Partner · 13 May 2021Compass Therapeutics acquired TRIGR Therapeutics, Inc. through a stock-for-stock transaction announced on May 13, 2021, with the deal expected to close in Q2 2021. The acquisition delivered CTX-009 (later renamed tovecimig), a promising bispecific antibody targeting DLL4 and VEGF-A, which has shown positive preliminary clinical results in solid tumors and became Compass's lead clinical-stage asset.
• Astellas PharmaminorStrategic or Co-development Partner · 1 January 2014Astellas Pharma acquired Audentes Therapeutics, a company co-founded by Compass CEO Thomas J. Schuetz, in a transaction referenced in his biography. The relationship reflects historical venture connections rather than an active product partnership with Compass.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MacroGenics: Clinical-stage oncology company developing bispecific antibodies including PD-1 x PD-L1 candidates (lorigerlimab) and other immuno-oncology bispecifics; directly competes with CTX-8371 in the checkpoint bispecific space.
• Zymeworks: Clinical-stage biotech developing engineered multispecific antibodies, including bispecifics targeting oncology pathways; directly comparable platform-plus-pipeline model with proprietary antibody engineering technology.
• Harpoon Therapeutics: Clinical-stage company developing T cell engager bispecifics for oncology; comparable bispecific modality and clinical-stage positioning though focused on T cell engagers rather than checkpoint/angiogenesis bispecifics.
• Xencor: Clinical-stage biotech with a broad bispecific antibody pipeline using proprietary XmAb technology; comparable platform-driven approach to generating differentiated multispecific oncology therapeutics.
• Inhibrx Biosciences: Clinical-stage biotech developing multispecific biologics for oncology and rare diseases with proprietary single-domain antibody platform; comparable multispecific therapeutic approach and clinical-stage status.

Broad incumbents

• Regeneron: Large biopharmaceutical company with approved bispecific antibodies (linvoseltamab, odronextamab) and a VelociSuite antibody discovery platform; comparable bispecific modality and platform technology though operating at much larger scale with multiple marketed products.
• AstraZeneca (MedImmune): Large biopharmaceutical company with extensive bispecific antibody pipeline (e.g., datopotamab, volrustomig) and a history of antibody innovation through MedImmune; comparable bispecific therapeutic approach at much larger scale with multiple approved oncology antibodies.

Emerging players

• Adagene: Clinical-stage biotech with a power-driven antibody discovery and engineering platform targeting oncology; comparable platform-plus-pipeline structure though at earlier development stage.
• Atreca: Clinical-stage antibody discovery company using immune repertoire analysis to identify novel antibody therapeutics; comparable antibody discovery platform approach though with different technological foundation.
• Maverick Therapeutics: Emerging biotech developing conditionally active T cell engager bispecifics; comparable multispecific antibody modality with narrower therapeutic focus on T cell engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/6406601
• Xx.com/compassbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds10 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Compass Therapeutics